Reaching Consensus on the Adoption of Oncology Biosimilars

Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought™ commentaries!

Jeffrey Crawford, MD
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Rowena N. Schwartz, PharmD, BCOP

ClinicalThought

How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.

Rowena N. Schwartz, PharmD, BCOP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 14, 2018 Expired: No longer available for credit

Here’s my take on why some of the key reasons biosimilars may be an attractive cost-cutting measure in cancer care also pose a challenge to their widespread adoption.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 18, 2018 Expired: No longer available for credit

Herein, I summarize recent biosimilar approvals as well as how these agents might affect patient care and counseling in oncology practice.

Jeffrey Crawford, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 18, 2019 Expired: No longer available for credit
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational funding donation provided by
Amgen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue